Abstract:Perseris is a subcutaneous extended-release risperidone in situ forming implant (suspension) indicated for the treatment of adult schizophrenia. Owing to the release rate controlling polymer poly(lactide-co-glycolide) (PLGA), one injection of Perseris can deliver risperidone for one month, which significantly reduces the administration frequency and improves patient compliance. The PLGA and drug used in Perseris was previously identified through reverse engineering and two compositionally equivalent formulations (F-1 and F-2) showing similar in vitro drug release were developed. The current work focuses on in vivo exploration of Perseris and the developed compositionally equivalent formulations using a rabbit model and further evaluate the sameness of the developed formulations compared to Perseris. The in vivo pharmacokinetic (PK) profiles, drug absorption rate, phase separation rate, macro appearance, weight loss as well as the water uptake of the solidified drug depots at different time points were investigated and compared with the in vitro release data as well as with dog and human in vivo data available in literature. Results show that the rabbit PK profile of Perseris was relevant with those obtained from both the dog model and the clinical data, indicating that the rabbit model is appropriate for investigation of the in vivo performance of risperidone implants. Consistent with their similar in vitro drug release, the two compositionally equivalent formulations demonstrated similar PK profiles, drug absorption rates, weight loss and swelling in vivo compared to Perseris. Although the erosion mechanism appeared to be similar between in vitro and in vivo , there were in vitro-in vivo differences concerning the drug release kinetics, phase separation rates and swelling behavior. This work provides a comprehensive in vitro / in vivo understanding of Perseris and the developed compositionally equivalent formulations, which will be beneficial for future development of generic as well as novel PLGA in situ forming implant products.

Biodegradable Poly(d, L-lactide-co-glycolide) (PLGA) Microspheres for Sustained Release of Risperidone: Zero-order Release Formulation.

Effects of Formulation Parameters on Encapsulation Efficiency and Release Behavior of Risperidone Poly(d,l-Lactide-co-glycolide) Microsphere.

An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics

Development and Characterization of Long-Acting Injectable Risperidone Microspheres Using Biodegradable Polymers: Formulation Optimization and Release Kinetics

Preparation and in vitro evaluation of risperidone loaded PLGA microspheres

Development of a novel 3-month drug releasing risperidone microspheres

Risperidone-loaded Long-Acting Injectable Microspheres Prepared by Ultra-Fine Particle Processing System

Pharmacokinetics and Pharmacodynamics Evaluation on Risperidone-Containing Microsphere Fabricated by Ultra-Fine Particle Processing System

Effect of Bases with Different Solubility on the Release Behavior of Risperidone Loaded Plga Microspheres

Study on pramipexole dihydrochloride sustained-release tablets

Formation Mechanism and in Vitro Evaluation of Risperidone-Containing PLGA Microspheres Fabricated by Ultrafine Particle Processing System.

Preparation and in Vitro Release of Risperidone Injectable Biodegradable Implants

Long-Acting Risperidone Dual Control System: Preparation, Characterization and Evaluation In Vitro and In Vivo

Modulation of Release Rates of Risperidone Loaded Microspheres by Mg(OH)_2

Engineered PLGA microspheres for extended release of brexpiprazole: in vitro and in vivo studies

Control of encapsulation efficiency and morphology of poly(lactide-co-glycolide) microparticles with a diafiltration-driven solvent extraction process

Preparation, Characterization And In Vitro Release Properties Of Ibuprofen-Loaded Microspheres Based On Polylactide, Poly(Epsilon-Caprolactone) And Their Copolymers

Preparation, characterization and in vitro release properties of ibuprofen-loaded microspheres based on polylactide, poly(ε-caprolactone) and their copolymers

Microfluidic preparation of monodisperse PLGA-PEG/PLGA microspheres with controllable morphology for drug release.

In vivo characterization of Perseris and compositionally equivalent formulations

A Uniform Ultra-Small Microsphere/SAIB Hybrid Depot with Low Burst Release for Long-Term Continuous Drug Release